|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2010-12-29
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
The Cancer and Leukemia Group B (CALGB) conducted a phase II study evaluating sunitinib in patients with progressive metastatic pancreas adenocarcinoma following prior gemcitabine-based therapy (trial CALGB 80603; ClinicalTrials.gov identifier, NCT00397787). The primary endpoint was to determine the disease control rate (DCR) as measured by the Response Evaluation Criteria in Solid Tumors (complete response, partial response [PR], and stable disease) at 6 weeks.
|
|
pubmed:grant |
http://linkedlifedata.com/resource/pubmed/grant/CA04326,
http://linkedlifedata.com/resource/pubmed/grant/CA08025,
http://linkedlifedata.com/resource/pubmed/grant/CA11789,
http://linkedlifedata.com/resource/pubmed/grant/CA31946,
http://linkedlifedata.com/resource/pubmed/grant/CA32291,
http://linkedlifedata.com/resource/pubmed/grant/CA33601,
http://linkedlifedata.com/resource/pubmed/grant/CA35113,
http://linkedlifedata.com/resource/pubmed/grant/CA35279,
http://linkedlifedata.com/resource/pubmed/grant/CA41287,
http://linkedlifedata.com/resource/pubmed/grant/CA45389,
http://linkedlifedata.com/resource/pubmed/grant/CA45418,
http://linkedlifedata.com/resource/pubmed/grant/CA45808,
http://linkedlifedata.com/resource/pubmed/grant/CA47577,
http://linkedlifedata.com/resource/pubmed/grant/CA47642,
http://linkedlifedata.com/resource/pubmed/grant/CA77298,
http://linkedlifedata.com/resource/pubmed/grant/CA77406,
http://linkedlifedata.com/resource/pubmed/grant/CA77440,
http://linkedlifedata.com/resource/pubmed/grant/CA77597,
http://linkedlifedata.com/resource/pubmed/grant/CA77651,
http://linkedlifedata.com/resource/pubmed/grant/CA77658,
http://linkedlifedata.com/resource/pubmed/grant/CA86726
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1549-490X
|
|
pubmed:author |
pubmed-author:Abou-AlfaGhassan KGK,
pubmed-author:Bekaii-SaabTaniosT,
pubmed-author:Cancer and Leukemia Group B,
pubmed-author:DouglasKatheK,
pubmed-author:GoldbergRichard MRM,
pubmed-author:HallMargaretM,
pubmed-author:HollisDonnaD,
pubmed-author:KindlerHedy LHL,
pubmed-author:NiedzwieckiDonnaD,
pubmed-author:O'ReillyEileen MEM,
pubmed-author:PluardTimothyT,
pubmed-author:SchilskyRichard LRL
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1310-9
|
|
pubmed:meshHeading |
pubmed-meshheading:21148613-Adenocarcinoma,
pubmed-meshheading:21148613-Adult,
pubmed-meshheading:21148613-Aged,
pubmed-meshheading:21148613-Aged, 80 and over,
pubmed-meshheading:21148613-Antineoplastic Agents,
pubmed-meshheading:21148613-Bone Neoplasms,
pubmed-meshheading:21148613-Female,
pubmed-meshheading:21148613-Humans,
pubmed-meshheading:21148613-Indoles,
pubmed-meshheading:21148613-Liver Neoplasms,
pubmed-meshheading:21148613-Lung Neoplasms,
pubmed-meshheading:21148613-Lymphatic Metastasis,
pubmed-meshheading:21148613-Male,
pubmed-meshheading:21148613-Middle Aged,
pubmed-meshheading:21148613-Neoplasm Staging,
pubmed-meshheading:21148613-Pancreatic Neoplasms,
pubmed-meshheading:21148613-Pyrroles,
pubmed-meshheading:21148613-Salvage Therapy,
pubmed-meshheading:21148613-Survival Rate,
pubmed-meshheading:21148613-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603).
|
|
pubmed:affiliation |
Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA. oreillye@mskcc.org
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II,
Research Support, N.I.H., Extramural
|
